CoChat
Cited by 2,033

The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Open access
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., Winer, E. · 2017 · Annals of Oncology

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6].

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw544

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 12

  1. Howlader, 2016, SEER Cancer Statistics Review, 1975–2013
  2. Schrijver, 2016, Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer, Mod Pathol, 10.1038/modpathol.2016.116 · doi:10.1038/modpathol.2016.116
  3. Soran, 2016, A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01), J Clin Oncol, 34
  4. Ellis, 2015, Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study, J Clin Oncol, 33
  5. Urruticoechea, 2016, PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.504 · doi:10.1200/jco.2016.34.15_suppl.504
  6. Rayson, 2014, Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact, Breast J, 20, 408, 10.1111/tbj.12284 · doi:10.1111/tbj.12284
  7. Andersson, 2015, The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis, J Clin Oncol, 33, 586., 10.1200/jco.2015.33.15_suppl.586 · doi:10.1200/jco.2015.33.15_suppl.586
  8. Tutt, 2015, TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer, Cancer Res, 75, S3
  9. Cortes, 2015, Overall survival (OS) from the phase 2 study of enzalutamide, an androgen receptor (AR) signaling inhibitor, in ar+ advanced triple-negative breast cancer (aTNBC), Eur J Cancer, 51
  10. Himelstein, 2015, CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.9501 · doi:10.1200/jco.2015.33.15_suppl.9501
  11. VEJonesLLJensenKJMcIntyre. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: preliminary results of a randomized phase II study. 2015 San Antonio Breast Cancer Symposium; December 5–8, 2015; San Antonio, TX. Abstract P1-15-06. · doi:10.1158/1538-7445.sabcs15-p1-15-06
  12. Rugo, 2016, Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial, J Clin Oncol, 34, 10.1200/jco.2016.34.26_suppl.189 · doi:10.1200/jco.2016.34.26_suppl.189

Cited by

See all 2,033

Metadata

Authors
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M. J., Pierga, J. Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., & Winer, E.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-01
Volume
28
Issue
1
Pages
16-33
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2560635244
Cited by
2,033
References
167
FWCI
62.84
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.